

# Jean Hoffman-Censits

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5731737/publications.pdf>

Version: 2024-02-01

28  
papers

7,470  
citations

706676

14  
h-index

651938

25  
g-index

28  
all docs

28  
docs citations

28  
times ranked

10064  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer. <i>European Urology</i> , 2022, 81, 138-142.	0.9	12
2	Safety and Efficacy of Reproductive Organ-Sparing Radical Cystectomy in Women With Variant Histology and Advanced Stage. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 60-68.	0.9	6
3	Residual CIS after neoadjuvant chemotherapy and radical cystectomy for muscle invasive bladder cancer: Implications for neoadjuvant trials. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	0.8	0
4	Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile. <i>European Urology Oncology</i> , 2021, 4, 297-300.	2.6	18
5	Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2021, 79, 364-371.	0.9	41
6	Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 176-181.	0.9	7
7	Understanding Psychosocial and Sexual Health Concerns Among Women With Bladder Cancer Undergoing Radical Cystectomy. <i>Urology</i> , 2021, 151, 145-153.	0.5	13
8	Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 525-537.	5.1	225
9	Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 788.e15-788.e21.	0.8	2
10	New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer – What do we understand so far?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 619-622.	0.8	7
11	Urothelial Carcinoma In Situ of the Bladder: Correlation of CK20 Expression With Adaptive Immune Resistance, Response to BCG Therapy, and Clinical Outcome. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, 29, 127-135.	0.6	5
12	Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. <i>Cancer</i> , 2020, 126, 2597-2606.	2.0	39
13	Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma. , 2020, 8, e000419.		7
14	Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2020, 203, 690-698.	0.2	76
15	Reply by Authors. <i>Journal of Urology</i> , 2020, 203, 697-698.	0.2	0
16	Recent developments in the treatment of advanced bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 109-114.	0.8	34
17	Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e521-e524.	0.9	18
18	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. <i>Lancet</i> , The, 2017, 389, 67-76.	6.3	1,728

#	ARTICLE	IF	CITATIONS
19	Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nature Communications, 2017, 8, 2193.	5.8	99
20	Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations. OncoTargets and Therapy, 2017, Volume 10, 4089-4098.	1.0	8
21	Combination immunotherapy in genitourinary malignancies. Current Opinion in Urology, 2016, 26, 523-528.	0.9	4
22	Clinical Validation of Chemotherapy Response Biomarker <i>ERCC2</i> in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncology, 2016, 2, 1094.	3.4	205
23	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet, The, 2016, 387, 1909-1920.	6.3	3,077
24	Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. European Urology, 2015, 68, 959-967.	0.9	395
25	Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. Journal of Clinical Oncology, 2014, 32, 4171-4172.	0.8	1
26	Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy. Cancer Cell, 2014, 25, 152-165.	7.7	1,358
27	Chemotherapy and Targeted Therapies: Are We Making Progress in Castrate-Resistant Prostate Cancer?. Seminars in Oncology, 2013, 40, 361-374.	0.8	15
28	Enzalutamide: A Novel Antiandrogen for Patients with Castrate-Resistant Prostate Cancer. Clinical Cancer Research, 2013, 19, 1335-1339.	3.2	70